Sangamo completes acquisition of TxCell

04-Dec-2018 - Sangamo Therapeutics, Inc. announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market. “The acquisition of TxCell immediately positions Sangamo as the leader in CAR-Treg development,” said Sandy Macrae, CEO ...

Sangamo Therapeutics to acquire TxCell

24-Jul-2018 - Sangamo Therapeutics and TxCell announced that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, following the completion of the contemplated acquisition of a majority stake of TxCell, file a simplified cash tender offer for the purchase of all then ...

Sigma-Aldrich and Sangamo BioSciences Announce Alliance to Develop Zinc Finger-Based Laboratory Research Reagents

13-Jul-2007 - Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. announced a significant alliance focused on the development of high value laboratory research reagents based upon Sangamo's ZFP technology. The alliance combines Sigma's global marketing capabilities and reputation as a provider of high ...

Dow AgroSciences and Sangamo BioSciences Announce the Achievement of Multiple Milestones in Plant Agriculture Collaboration

20-Nov-2006 - Dow AgroSciences LLC and Sangamo BioSciences, Inc. announced the successful completion of multiple research milestones as part of their Research and Commercial License Agreement initiated October 2005. The three-year agreement provides Dow AgroSciences with access to Sangamo's proprietary zinc ...

Dow AgroSciences, Sangamo BioSciences Announce Research and Commercial License Agreement in Plant Agriculture

07-Oct-2005 - Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, and Sangamo BioSciences, Inc. announced the signing of a Research and Commercial License Agreement. The agreement provides Dow AgroSciences with access to Sangamo's proprietary zinc finger DNA-binding protein (ZFP) ...

Novo Nordisk and Sangamo BioSciences Announce Agreement

12-Sep-2005 - Novo Nordisk A/S and Sangamo BioSciences, Inc. announced an agreement that provides Novo Nordisk with access to Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology. Sangamo will provide its ZFP technology for Novo Nordisk to evaluate for use in the field of enhanced protein ...

Sangamo BioSciences Receives $2 Million Advanced Technology Program

Third ATP Grant Awarded to Company

05-May-2004 - Richmond, Calif. -- Sangamo BioSciences, Inc. announced that the company has been awarded an Advanced Technology Program (ATP) grant to conduct research on a novel application of Sangamo's zinc finger DNA binding protein transcription factor (ZFP TF) technology. The grant, worth $2 million, was ...